Skip to main content

Table 3 Complications and adverse events

From: Comparison of the efficacy and safety of URSL, RPLU, and MPCNL for treatment of large upper impacted ureteral stones: a randomized controlled trial

Variable

URSL group

MPCNL group

RPUL group

P valuea

P valueb

P valuec

Grade I

 Pain

6/46(13%)

8/50(16%)

9/48(18%)

0.276

0.027

0.795

 Fever

2/46(4.3%)

3/50(6%)

2/48(4.2%)

0.735

0.658

0.743

 Nausea/vomiting

2/46(4.3%)

1/50(2%)

3/48(6%)

0.273

0.342

0.042

 Urine leakage

0/46(0%)

0/50(0%)

3/48(6%)

NS

<0.001

<0.001

Grade II

 Minor pelvic/ureter perforation

3/46(6.5%)

0/50(0%)

0/48(0%)

<0.001

<0.001

NS

 Urinary tract infection

1/46(3%)

1/50(2%)

0/48(0%)

NS

<0.001

<0.001

 Ureteral stricture

2/46(4.3%)

0/50(0%)

0/48(0%)

<0.001

<0.001

NS

Grade III

 Blood transfusion

0/46(0%)

3/50(6%)

0/48(0%)

<0.001

NS

<0.001

 Grade III - V

0/46(0%)

0/50(0%)

0/48(0%)

NS

NS

NS

  1. aURSL vs. MPCNL; bURSL vs. RPUL; c MPCNL vs. RPUL; NS No Significance